

**GOVERNING BOARD OF
THE GLOBAL HEALTH EDCTP3 JOINT UNDERTAKING
DECISION N° GB/24/2025**

**Approving the application of LRI to become contributing partner of the
Global Health EDCTP3 Joint Undertaking under the Call Topic
HORIZON-JU-GH-EDCTP3-2026-01-TB-01-two-stage: Global
collaboration action for the development of TB drugs for therapy and
chemoprophylaxis in adults and children in sub-Saharan Africa**

THE GOVERNING BOARD OF THE GLOBAL HEALTH EDCTP3 JOINT UNDERTAKING (hereafter “Global Health EDCTP3 JU”),

Having regard to Council Regulation (EU) No 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014 (hereafter “the Founding Regulation”), in particular Articles 2(7), 9, 11(5), 17(2)(c) and 102(b) thereof,

WHEREAS:

- (1) On 17 September 2025, the Leprosy Research Initiative (LRI) submitted a letter of endorsement to the Governing Board requesting to become a contributing partner to the Global Health EDCTP3 Joint Undertaking.
- (2) LRI requests to contribute to the 2026 Work Programme and in particular HORIZON-JU-GH-EDCTP3-2026-01-TB-01-two-stage: Global collaboration action for the development of TB drugs for therapy and chemoprophylaxis in adults and children in sub-Saharan Africa.
- (3) The expected contribution of LRI is estimated to EUR 400,000 and consists in financial contributions.
- (4) The Governing Board should assess the letter of endorsement and approve or reject the application.

HAS ADOPTED THIS DECISION:

Article 1

The application is hereby accepted by the Governing Board.

Article 2

This decision shall enter into force on the day of its adoption.

Done at Brussels, 28 November 2025.

For the Global Health EDCTP3 Joint Undertaking Governing Board

Henning Gädeke
Chairperson of the Governing Board

Annex:

1. Letter of endorsement from LRI